Novartis AG (NOVN.SW) analysis

Loading the Vaultflake…

Health is the drug company's debt, not of a patent with no date. Quality separates the oncology margin from the rest of the medicines. Growth follows sales collected, not a launch year. P/E is read against that year, not against that peak. Shareholder return is the dividend, checked against cash. Do not read it as the generics business, which is another company now.

The P/E of a launch year is not the earnings if the payer cuts the price. EV/EBITDA is read without treating the trial as a sale. Do not use Roche's multiple as if oncology and the rest were the same book at both companies. A dash if the NOVN.SW cache is cold.

Limits of this report

Not advice on Novartis. Vaultflake does not date the patent and does not describe the medicine. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report